Enlaza Therapeutics is at the forefront of developing a novel class of protein therapeutics known as covalent biologics, which aim to enhance the treatment of cancer and other serious diseases. Central to their approach is the proprietary War-Lock™ technology, which facilitates the creation of highly selective biologic drugs capable of forming irreversible bonds with disease-related targets. This technology leverages a unique synthetic biology platform that incorporates unnatural amino acids into protein drugs, allowing for precise covalent binding. The result is a therapeutic modality that can achieve sustained occupancy of targets while minimizing systemic exposure, thereby improving both efficacy and safety profiles compared to traditional protein therapeutics.

The War-Lock platform not only enables the engineering of biologics with enhanced therapeutic specificity but also allows for the development of various drug formats, including antibody-drug conjugates (ADCs) and radioligand therapies (RLTs). Enlaza's innovative approach addresses the limitations of standard protein drugs, which often require continuous dosing due to reversible binding. By ensuring that their therapeutics can lock irreversibly onto targets, Enlaza aims to reduce off-target effects and toxicity, ultimately leading to safer and more effective treatment options for patients. The company is building a robust pipeline of covalent biologics, with a focus on oncology, and is positioned to transform the landscape of therapeutic protein development.

United States

Enlaza Therapeutics is pioneering the field of covalent biologics.  These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics. 

Enlaza Therapeutics

Company Details